References
- Young LS , RickinsonAB. Epstein–Barr virus: 40 years on. Nat. Rev. Cancer4(10) , 757–768 (2004).
- Stein RA . Epigenetics – the link between infectious diseases and cancer. JAMA305(14) , 1484–1485 (2011).
- Shah KM , YoungLS. Epstein–Barr virus and carcinogenesis: beyond Burkitt‘s lymphoma. Clin. Microbiol. Infect.15(11) , 982–988 (2009).
- Ryan JL , JonesRJ, KenneySCet al. Epstein–Barr virus-specific methylation of human genes in gastric cancer cells. Infect. Agent. Cancer 5 , 27 (2010).
- Wei WI , ShamJS. Nasopharyngeal carcinoma. Lancet365(9476) , 2041–2054 (2005).
- Loyo M , BraitM, KimMSet al. A survey of methylated candidate tumor suppressor genes in nasopharyngeal carcinoma. Int. J. Cancer 128(6) , 1393–1403 (2011).
References
- Risbridger GP , DavisID, BirrellSN, TilleyWD. Breast and prostate cancer: more similar than different. Nat. Rev. Cancer10(3) , 205–212 (2010).
- Yamamoto M , CidE, BruS, YamamotoF. Rare and frequent promoter methylation, respectively, of TSHZ2 and 3 genes that are both downregulated in expression in breast and prostate cancers. PLoS ONE6(3) , e17149 (2011).
- McGinnis W , KrumlaufR. Homeobox genes and axial patterning. Cell68(2) , 283–302 (1992).
- Yamamoto M , MetokiR, YamamotoF. Systematic multiplex polymerase chain reaction and reverse transcription-polymerase chain reaction analyses of changes in copy number and expression of proto-oncogenes and tumor suppressor genes in cancer tissues and cell lines. Electrophoresis25(20) , 3349–3356 (2004).
References
- Maris JM . Recent advances in neuroblastoma. N. Engl. J. Med.362 , 2202–2211 (2010).
- Park JR , EggertA, CaronH. Neuroblastoma: biology, prognosis, and treatment. Hematol. Oncol. Clin. North Am.24 , 65–86 (2010).
- Buckley PG , DasS, BryanKet al. Genome-wide DNA methylation analysis of neuroblastic tumors reveals clinically relevant epigenetic events and large-scale epigenomic alterations localized to telomeric regions. Int. J. Cancer 128 , 2296–2305 (2011).
- Grau E , OltraS, MartinezFet al. MAGE-A1 expression is associated with good prognosis in neuroblastoma tumors. J. Cancer Res. Clin. Oncol. 135 , 523–531 (2009).
- Hoebeeck J , MichelsE, PattynFet al. Aberrant methylation of candidate tumor suppressor genes in neuroblastoma. Cancer Lett. 273 , 336–346 (2009).
- Ohira M , NakagawaraA. Global genomic and RNA profiles for novel risk stratification of neuroblastoma. Cancer Sci.101 , 2295–2301 (2010).
- Caren H , DjosA, NethanderMet al. Identification of epigenetically regulated genes that predict patient outcome in neuroblastoma. BMC Cancer 11 , 66 (2011).
References
- Jemal A , SiegelR, XuJ, WardE. Cancer statistics, 2010. CA Cancer J. Clin.60(5) , 277–300 (2010).
- Linehan WM , PintoPA, SrinivasanRet al. Identification of the genes for kidney cancer: opportunity for disease-specific targeted therapeutics. Clin. Cancer. Res. 13(2 Pt 2) , 671S–679S (2007).
- Morrissey C , MartinezA, ZatykaMet al. Epigenetic inactivation of the RASSF1A 3p21.3 tumor suppressor gene in both clear cell and papillary renal cell carcinoma. Cancer Res. 61(19) , 7277–7281 (2001).
- Linehan WM , RubinJS, BottaroDP. VHL loss of function and its impact on oncogenic signaling networks in clear cell renal cell carcinoma. Int. J. Biochem. Cell Biol.41(4) , 753–756 (2009).
- Dahl E , WiesmannF, WoenckhausMet al. Frequent loss of SFRP1 expression in multiple human solid tumours: association with aberrant promoter methylation in renal cell carcinoma. Oncogene 26(38) , 5680–5691 (2007).
- Morris MR , RickettsCJ, GentleDet al. Genome-wide methylation analysis identifies epigenetically inactivated candidate tumour suppressor genes in renal cell carcinoma. Oncogene 30(12) , 1390–1401 (2011).